Skip to content
Clinical Trials – home

DEXLANSOPRAZOLE: A Comprehensive Guide for Patients

0 / 2
trials open to patients / all trials
1+
Countries

In short

This article examines the use of dexlansoprazole, a medication for treating acid-related disorders, in various clinical trials. These studies aim to assess the drug's effectiveness, safety, and potential applications in different patient populations, including adults and adolescents with conditions such as erosive esophagitis and gastroesophageal reflux disease (GERD).

At a glance

Main Conditions Studied
Erosive Esophagitis, Gastroesophageal Reflux Disease (GERD), Barrett's Esophagus
Age Groups
Adults, Adolescents (12-17 years)
Dosages Tested
30 mg, 60 mg, 90 mg (daily or twice daily)
Primary Outcomes
Healing of erosive esophagitis, maintenance of healing, relief of heartburn symptoms
Safety Assessments
Adverse events, vital signs, clinical laboratory tests
Study Designs
Randomized controlled trials, bioequivalence studies, open-label studies
Comparators
Placebo, lansoprazole, other formulations of dexlansoprazole
Duration of Studies
Ranging from single-dose to 36 weeks

What is Dexlansoprazole?

Dexlansoprazole is a medication used to treat various conditions related to stomach acid. It belongs to a class of drugs called proton pump inhibitors (PPIs). Dexlansoprazole is known by several brand names, including Dexilant, Kapidex, and DelanzoTMDR. This medication is designed to reduce the amount of acid your stomach produces, helping to relieve symptoms and promote healing in certain digestive disorders.

What Conditions Does Dexlansoprazole Treat?

Dexlansoprazole is used to treat several conditions related to excess stomach acid production:

  • Gastroesophageal Reflux Disease (GERD): This is a condition where stomach acid frequently flows back into the esophagus, causing symptoms like heartburn and regurgitation.
  • Erosive Esophagitis (EE): This is a severe form of GERD where stomach acid causes damage and inflammation to the lining of the esophagus.
  • Non-erosive GERD: This is a milder form of GERD where there's no visible damage to the esophagus, but symptoms are still present.
  • Maintenance of Healed Erosive Esophagitis: Dexlansoprazole is also used to prevent the recurrence of erosive esophagitis after it has been successfully treated.

How Does Dexlansoprazole Work?

Dexlansoprazole works by reducing the amount of acid your stomach produces. It does this by blocking a system in the cells of your stomach called the "proton pump." This pump is responsible for producing stomach acid. By inhibiting this pump, dexlansoprazole decreases the amount of acid in your stomach, which helps relieve symptoms and allows damaged tissue in the esophagus or stomach to heal.

Dosage Forms and Strengths

Dexlansoprazole comes in delayed-release capsules. These capsules are designed to release the medication in two stages as they pass through your digestive system, providing longer-lasting acid suppression. The common strengths available are:

  • 30 mg capsules
  • 60 mg capsules

The specific dosage prescribed will depend on the condition being treated and the individual patient's needs.

Clinical Studies and Effectiveness

Several clinical studies have been conducted to evaluate the effectiveness of dexlansoprazole:

  • Healing of Erosive Esophagitis: Studies have shown that dexlansoprazole is effective in healing erosive esophagitis. In one study, 60 mg and 90 mg doses of dexlansoprazole were compared to lansoprazole (another PPI) for healing erosive esophagitis over 8 weeks.
  • Maintenance of Healed Erosive Esophagitis: Research has also demonstrated that dexlansoprazole is effective in maintaining the healing of erosive esophagitis and providing relief from heartburn. A study in adolescents showed that after initial healing with 60 mg dexlansoprazole, a 30 mg dose was effective for maintaining healing over 16 weeks.
  • Non-cardiac Chest Pain: A study investigated the use of dexlansoprazole in treating non-cardiac chest pain related to GERD. This research aimed to determine if dexlansoprazole could help reduce the frequency and intensity of chest pain episodes.

Potential Side Effects

Like all medications, dexlansoprazole can cause side effects, although not everyone experiences them. Common side effects reported in clinical trials include:

  • Diarrhea
  • Abdominal pain
  • Nausea
  • Upper respiratory tract infection
  • Vomiting
  • Flatulence (gas)

It's important to note that these side effects were reported in studies, but their direct relationship to dexlansoprazole was not always clear. If you experience any persistent or severe side effects, you should contact your healthcare provider.

Use in Special Populations

Research has been conducted to understand how dexlansoprazole works in different populations:

  • Pediatric Use: Studies have been conducted in children and adolescents aged 1 to 17 years to evaluate the safety and effectiveness of dexlansoprazole in treating GERD and erosive esophagitis.
  • Ethnic Differences: A study was conducted to evaluate how dexlansoprazole is processed in the body (pharmacokinetics) of healthy Chinese participants. This type of research helps ensure that the medication is safe and effective across different ethnic groups.

It's important to note that the use of dexlansoprazole in pregnant women, nursing mothers, and patients with severe liver problems may require special consideration. Always consult with your healthcare provider about the appropriate use of this medication in your specific situation.

Questions people often ask

Conditions where Dexlansoprazole is being studied

Each condition opens its own overview and trial list

Trials with Dexlansoprazole

Recruiting trials first

See all 2 →
Quick filters
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).